AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34081966 — intervention group
Group type: EXPERIMENTAL
Intervention: LCI+EAC
Number of subjects: 1000
Study 34081966 — intervention group
Group type: EXPERIMENTAL
Intervention: LCI
Number of subjects: 1000
Study 34081966 — intervention group
Group type: EXPERIMENTAL
Intervention: EAC
Number of subjects: 1000
Study 34081966 — intervention group
Group type: COMPARATOR
Intervention: Standard HD colonoscopy
Number of subjects: 1000
Study 32278676 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline circulating tumor cell (bCTC) count ≥3
Number of subjects: 1202
Study 32278676 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAF mutated tumors
Number of subjects: 1202
Study 32278676 — intervention group
Group type: EXPERIMENTAL
Intervention: RAS mutated tumors
Number of subjects: 1202
Study 32278676 — intervention group
Group type: EXPERIMENTAL
Intervention: PIK3CA mutated tumors
Number of subjects: 1202
Study 32278676 — intervention group
Group type: EXPERIMENTAL
Intervention: High microsatellite instability (MSI)
Number of subjects: 1202
Study 35344464 — intervention group
Group type: EXPERIMENTAL
Intervention: sIPV (Sabin inactivated poliovirus vaccine)
Number of subjects: 300
Study 34581737 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact aspiration and stent retriever combined
Number of subjects: 405
Study 34581737 — intervention group
Group type: COMPARATOR
Intervention: Stent retriever alone
Number of subjects: 405
Study 32991589 — intervention group
Group type: EXPERIMENTAL
Intervention: Video intervention (n = 333)
Number of subjects: 1023
Study 32991589 — intervention group
Group type: EXPERIMENTAL
Intervention: Text intervention (n = 322)
Number of subjects: 1023
Study 32991589 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 368)
Number of subjects: 1023
Study 34605307 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet
Number of subjects: 35
Study 34605307 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet
Number of subjects: 35
Study 35244878 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother-Newborn Care Unit (MNCU)
Number of subjects: 0
Study 35244878 — intervention group
Group type: COMPARATOR
Intervention: Conventional NICU
Number of subjects: 0
Study 34203036 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam Rolling (FR)
Number of subjects: 65
Study 34203036 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Massage (MM)
Number of subjects: 65
Study 34203036 — intervention group
Group type: COMPARATOR
Intervention: Cognitively oriented relaxation routine (Control)
Number of subjects: 65
Study 34203036 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam Rolling (FR) and Manual Massage (MM)
Number of subjects: 65
Study 36056417 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis intervention
Number of subjects: 50
Study 36056417 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study 34965953 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus interferon alpha (BEV+IFN)
Number of subjects: 732
Study 34965953 — intervention group
Group type: COMPARATOR
Intervention: Interferon alpha alone (IFN)
Number of subjects: 732
Study 34965953 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab treatment with IL-6 and HGF
Number of subjects: 732
Study 34965953 — intervention group
Group type: EXPERIMENTAL
Intervention: Model based on IL-6, HGF and bevacizumab treatment
Number of subjects: 732
Study 36058418 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructed positive interaction + intranasal oxytocin
Number of subjects: 160
Study 36058418 — intervention group
Group type: COMPARATOR
Intervention: Control + intranasal oxytocin
Number of subjects: 160
Study 36058418 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructed positive interaction + placebo
Number of subjects: 160
Study 36058418 — intervention group
Group type: COMPARATOR
Intervention: Control + placebo
Number of subjects: 160
Study 36058418 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall group assignment
Number of subjects: 160
Study 36058418 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-α responses to wounding
Number of subjects: 160
Study 33159658 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg semaglutide
Number of subjects: 36
Study 33159658 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg semaglutide
Number of subjects: 36
Study 33159658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 32954593 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab plus erlotinib (RAM + ERL)
Number of subjects: 336
Study 32954593 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus erlotinib (PL + ERL)
Number of subjects: 336
Study 34605142 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-rapid lispro (URLi)
Number of subjects: 0
Study 34531736 — intervention group
Group type: EXPERIMENTAL
Intervention: Oroxylum indicum extract (500 mg, twice daily)
Number of subjects: 82
Study 34531736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 34531736 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Oroxylum indicum and placebo)
Number of subjects: 82
Study 32930550 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (activation letter)
Number of subjects: 236
Study 32930550 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (activation letter + financial incentive)
Number of subjects: 236
Study 32930550 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (activation letter + financial incentive + telephone call)
Number of subjects: 236
Study 32930550 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 236
Study 34271945 — intervention group
Group type: EXPERIMENTAL
Intervention: OPEN ARCH intervention (duration of 3, 6, or 9 months)
Number of subjects: 80
Study 34271945 — intervention group
Group type: COMPARATOR
Intervention: Control (participants served as their own control)
Number of subjects: 80
Study 33121454 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 187
Study 33121454 — intervention group
Group type: COMPARATOR
Intervention: Conscious Sedation (CS)
Number of subjects: 187
Study 34060903 — intervention group
Group type: EXPERIMENTAL
Intervention: Coarsened Exact Matching (CEM)
Number of subjects: 0
Study 34060903 — intervention group
Group type: EXPERIMENTAL
Intervention: Propensity Score Matching (PSM)
Number of subjects: 0
Study 34060903 — intervention group
Group type: EXPERIMENTAL
Intervention: CEM and PSM
Number of subjects: 0
Study 34918028 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV1) with TB treatment containing rifapentine (1200 mg), isoniazid, pyrazinamide, and either ethambutol or moxifloxacin
Number of subjects: 111
Study 34918028 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV2) with TB treatment containing rifapentine (1200 mg), isoniazid, pyrazinamide, and either ethambutol or moxifloxacin
Number of subjects: 111
Study 34887285 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of zoledronic acid
Number of subjects: 30
Study 34887285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 35973166 — intervention group
Group type: EXPERIMENTAL
Intervention: AI‐CNN model
Number of subjects: 1434
Study 35973166 — intervention group
Group type: COMPARATOR
Intervention: Routine practice (control group)
Number of subjects: 1434
Study 34327851 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut consumption
Number of subjects: 0
Study 34327851 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric carbohydrate bars
Number of subjects: 0
Study 34591982 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg
Number of subjects: 2436
Study 34591982 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg
Number of subjects: 2436
Study 34591982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2436
Study 34591982 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmarketing data
Number of subjects: 2436
Study 36260385 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education via Instagram for 5 weeks
Number of subjects: 49
Study 36260385 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 49
Study 32472610 — intervention group
Group type: EXPERIMENTAL
Intervention: Gains in 7p22 (8.5%)
Number of subjects: 100
Study 32472610 — intervention group
Group type: EXPERIMENTAL
Intervention: Gains of 11q (CCND1)
Number of subjects: 100
Study 32472610 — intervention group
Group type: EXPERIMENTAL
Intervention: Deletions of 17p (TP53) and 9p (CDKN2A)
Number of subjects: 100
Study 35315830 — intervention group
Group type: EXPERIMENTAL
Intervention: Arch-support insoles
Number of subjects: 20
Study 35315830 — intervention group
Group type: COMPARATOR
Intervention: Flat insoles
Number of subjects: 20
Study 34661664 — intervention group
Group type: COMPARATOR
Intervention: High-dose deutetrabenazine (up to 48 mg/d)
Number of subjects: 158
Study 34661664 — intervention group
Group type: COMPARATOR
Intervention: Low-dose deutetrabenazine (up to 36 mg/d)
Number of subjects: 158
Study 34661664 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 158
Study 34661664 — intervention group
Group type: COMPARATOR
Intervention: High-dose deutetrabenazine
Number of subjects: 158
Study 34661664 — intervention group
Group type: COMPARATOR
Intervention: Low-dose deutetrabenazine
Number of subjects: 158
Study 35156511 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured postoperative rehabilitation
Number of subjects: 149
Study 35156511 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative approach
Number of subjects: 149
Study 34418139 — intervention group
Group type: EXPERIMENTAL
Intervention: ROLE‐AP programme over a 3‐week period
Number of subjects: 30
Study 34418139 — intervention group
Group type: COMPARATOR
Intervention: Normal routine (Control)
Number of subjects: 30
Study 34391242 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascial therapy, strength training, and kinesiotaping
Number of subjects: 36
Study 34391242 — intervention group
Group type: COMPARATOR
Intervention: Myofascial techniques and eccentric training (control)
Number of subjects: 36
Study 33247774 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial Cellulose (BC) dressing
Number of subjects: 26
Study 33247774 — intervention group
Group type: COMPARATOR
Intervention: Vaseline with gauze
Number of subjects: 26
Study 35936372 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative psychological nursing intervention combined with traditional preoperative education
Number of subjects: 60
Study 35936372 — intervention group
Group type: COMPARATOR
Intervention: Traditional preoperative education
Number of subjects: 60
Study 32778992 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined (ADHD + tobacco) intervention
Number of subjects: 63
Study 32778992 — intervention group
Group type: COMPARATOR
Intervention: ADHD only intervention
Number of subjects: 63
Study 36450422 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue RAS inhibiting therapy
Number of subjects: 215
Study 36450422 — intervention group
Group type: COMPARATOR
Intervention: Discontinue RAS inhibiting therapy
Number of subjects: 215
Study 36450422 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue RAS inhibiting therapy (mechanistic substudy)
Number of subjects: 215
Study 36450422 — intervention group
Group type: COMPARATOR
Intervention: Discontinue RAS inhibiting therapy (mechanistic substudy)
Number of subjects: 215
Study 33386890 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape powder (46 g, equivalent to 252 g fresh grapes)
Number of subjects: 25
Study 33386890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 32253602 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer survivors (CS)
Number of subjects: 263
Study 32253602 — intervention group
Group type: COMPARATOR
Intervention: Cancer-free controls
Number of subjects: 263
Study 32894871 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Milking (UCM)
Number of subjects: 56
Study 32894871 — intervention group
Group type: COMPARATOR
Intervention: Immediate Cord Clamping (ICC)
Number of subjects: 56
Study 33246495 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-faceted community and clinic-based strategies including expanded community health worker services, home BP self-monitoring, and a storytelling intervention delivered via DVDs at baseline and at 3, 6, and 9 months.
Number of subjects: 680
Study 33246495 — intervention group
Group type: COMPARATOR
Intervention: Multi-level intervention modeled after the Vietnam National Hypertension Program including education and practice change modules for health care providers, accessible reading materials for patients, and a multi-media community awareness program.
Number of subjects: 680
Study 35779491 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19 vaccine
Number of subjects: 15169
Study 35779491 — intervention group
Group type: COMPARATOR
Intervention: Control product
Number of subjects: 15169
Study 34480873 — intervention group
Group type: EXPERIMENTAL
Intervention: Midurethral sling
Number of subjects: 324
Study 34480873 — intervention group
Group type: COMPARATOR
Intervention: Sham incisions
Number of subjects: 324
Study 34480873 — intervention group
Group type: EXPERIMENTAL
Intervention: Midurethral sling and Sham incisions
Number of subjects: 324
Study 35962939 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 10 mg (every 8 weeks)
Number of subjects: 2025
Study 35962939 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 5 mg (every 8 weeks)
Number of subjects: 2025
Study 35962939 — intervention group
Group type: COMPARATOR
Intervention: Tramadol (100–300 mg/day)
Number of subjects: 2025
Study 35962939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2025
Study 32591267 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 70
Study 32591267 — intervention group
Group type: COMPARATOR
Intervention: Routine preconception care
Number of subjects: 70
Study 36433716 — intervention group
Group type: EXPERIMENTAL
Intervention: Core Stabilisation (CS) Group
Number of subjects: 51
Study 36433716 — intervention group
Group type: EXPERIMENTAL
Intervention: Auxiliary Respiratory Muscles Exercise (ARM) Group
Number of subjects: 51
Study 36433716 — intervention group
Group type: COMPARATOR
Intervention: Control (C) Group
Number of subjects: 51
Study 34491803 — intervention group
Group type: EXPERIMENTAL
Intervention: SPR720 (100 to 2000 mg single doses or 500 to 1500 mg daily doses for 7 or 14 days)
Number of subjects: 96
Study 34491803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 34491803 — intervention group
Group type: EXPERIMENTAL
Intervention: SPR720
Number of subjects: 96
Study 32304881 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 80
Study 35338430 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiao-Tai-Wan
Number of subjects: 50
Study 35338430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 35338430 — intervention group
Group type: COMPARATOR
Intervention: Healthy Control
Number of subjects: 50
Study 32744369 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% bimatoprost ophthalmic solution
Number of subjects: 10
Study 32744369 — intervention group
Group type: COMPARATOR
Intervention: 0.1% tacrolimus ointment
Number of subjects: 10
Study 32744369 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (bimatoprost and tacrolimus)
Number of subjects: 10
Study 34728124 — intervention group
Group type: EXPERIMENTAL
Intervention: EBNPG knowledge training
Number of subjects: 0
Study 34728124 — intervention group
Group type: EXPERIMENTAL
Intervention: EBNPG knowledge training plus an implementation toolkit
Number of subjects: 0
Study 34728124 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 32896775 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 160 mg/day
Number of subjects: 0
Study 33933738 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased serum calcium levels (per 0.5 mg/dL)
Number of subjects: 61079
Study 36444676 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention
Number of subjects: 280
Study 36444676 — intervention group
Group type: COMPARATOR
Intervention: Self-help group
Number of subjects: 280
Study 32737900 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide at a dose of 20 ppm added to the sweep gas during CPB
Number of subjects: 40
Study 32737900 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sweep gas without nitric oxide)
Number of subjects: 40
Study 34399427 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen-enriched air (40% O2)
Number of subjects: 10
Study 33611164 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic oral vinorelbine (mVNR) at a fixed dose of 50 mg × 3
Number of subjects: 167
Study 33611164 — intervention group
Group type: COMPARATOR
Intervention: Standard schedule of vinorelbine (60-80 mg/m2 weekly)
Number of subjects: 167
Study 33611164 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic oral vinorelbine (mVNR)
Number of subjects: 167
Study 33611164 — intervention group
Group type: COMPARATOR
Intervention: Standard schedule of vinorelbine
Number of subjects: 167
Study 32378956 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress reappraisal
Number of subjects: 266
Study 32378956 — intervention group
Group type: COMPARATOR
Intervention: Emotional suppression
Number of subjects: 266
Study 32378956 — intervention group
Group type: COMPARATOR
Intervention: Control (no instructions)
Number of subjects: 266
Study 36461128 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychoeducation program
Number of subjects: 50
Study 36461128 — intervention group
Group type: COMPARATOR
Intervention: Waiting list arm (Control)
Number of subjects: 50
Study 34271465 — intervention group
Group type: EXPERIMENTAL
Intervention: Palisade grass (Urochloa brizantha cv. Marandu)
Number of subjects: 3
Study 34271465 — intervention group
Group type: EXPERIMENTAL
Intervention: Eucalypt (Eucalyptus urophylla x Eucalyptus grandis)
Number of subjects: 3
Study 34271465 — intervention group
Group type: EXPERIMENTAL
Intervention: Indian mustard (Brassica juncea L.)
Number of subjects: 3
Study 34271465 — intervention group
Group type: COMPARATOR
Intervention: No plant control
Number of subjects: 3
Study 36223056 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 monthly injections of intravitreal ranibizumab (IVR) + pro re nata (PRN) dosing
Number of subjects: 74
Study 36223056 — intervention group
Group type: COMPARATOR
Intervention: 1 initial injection of intravitreal ranibizumab (IVR) + pro re nata (PRN) dosing
Number of subjects: 74
Study 33377600 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group with task-state fMRI results
Number of subjects: 34
Study 33377600 — intervention group
Group type: COMPARATOR
Intervention: Control group with hollowing and multiple subpial transection operation only
Number of subjects: 34
Study 35149535 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccination
Number of subjects: 3341
Study 35149535 — intervention group
Group type: COMPARATOR
Intervention: Non-HPV vaccination (control)
Number of subjects: 3341
Study 32891527 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity monitor with virtual activity groups
Number of subjects: 120
Study 32891527 — intervention group
Group type: COMPARATOR
Intervention: Activity monitor without virtual activity groups
Number of subjects: 120
Study 32891527 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study 32522420 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HLA)-based vaginal gel, used daily for the first 2 weeks, then 3 times/week until weeks 12-14, increased to 5 times/week for non-responders.
Number of subjects: 43
Study 32522420 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HLA)-based vaginal gel
Number of subjects: 43
Study 34015342 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziltivekimab 7.5 mg
Number of subjects: 264
Study 34015342 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziltivekimab 15 mg
Number of subjects: 264
Study 34015342 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziltivekimab 30 mg
Number of subjects: 264
Study 34015342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 34213494 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μg/kg intravenous injection)
Number of subjects: 105
Study 34213494 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (10 mg/kg intravenous injection)
Number of subjects: 105
Study 34213494 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (0.5 μg/kg intravenous injection)
Number of subjects: 105
Study 34213494 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 105
Study 35526835 — intervention group
Group type: COMPARATOR
Intervention: IHC 0+ without staining
Number of subjects: 0
Study 35526835 — intervention group
Group type: COMPARATOR
Intervention: IHC 0+ with some staining
Number of subjects: 0
Study 35526835 — intervention group
Group type: COMPARATOR
Intervention: IHC 1+
Number of subjects: 0
Study 32847382 — intervention group
Group type: EXPERIMENTAL
Intervention: Panna wire
Number of subjects: 100
Study 32847382 — intervention group
Group type: COMPARATOR
Intervention: Conventional wire
Number of subjects: 100
Study 36229383 — intervention group
Group type: EXPERIMENTAL
Intervention: IV paracetamol
Number of subjects: 106
Study 36229383 — intervention group
Group type: EXPERIMENTAL
Intervention: IV dexketoprofen trometamol
Number of subjects: 106
Study 36229383 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine
Number of subjects: 106
Study 36229383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 33878341 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message-based intervention (3 automated messages per day for 12 weeks)
Number of subjects: 42
Study 33878341 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message-based intervention
Number of subjects: 42
Study 33878341 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 42
Study 33852743 — intervention group
Group type: EXPERIMENTAL
Intervention: Static loading with a crosshead speed of 0.5 mm/min
Number of subjects: 20
Study 33852743 — intervention group
Group type: EXPERIMENTAL
Intervention: Step‐stress cyclic loading (1 Hz) with increasing amplitude
Number of subjects: 20